24
STAT3 Inhibitors and Their Anti-Cancer Usage
The Ohio State University
Small molecule
Oncology
Hit To Lead or Lead Optimization
Researchers at the Ohio State University, led by Dr. Chenglong Li, have designed novel, non-peptidomimetic molecules for use as anti-cancer inhibitors of STAT3, a protein involved in gene expression and associated with various cancers. The molecules were developed using Fragment-based Drug Design (FBDD) and tested for half maximal inhibitory concentration (IC50).
US 9783513 B2